BG Medicine Inc Prices Public Offering Of Common Stock

BG Medicine Inc announced the sale of 6,000,000 shares of common stock in an underwritten public offering at a price to the public of $2.00 per share. The net offering proceeds to BG Medicine from the sale of the shares are expected to be approximately $11.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriter's over-allotment option. BG Medicine anticipates using the net proceeds from this offering for operations, including, advancing the commercialization of cardiovascular diagnostic tests in the United States and Europe; and other general corporate purposes, including capital expenditures, licensing of intellectual property, repayment of indebtedness and working capital. The offering is expected to close on or about January 30, 2013, subject to customary closing conditions. In addition, BG Medicine has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any. Lazard Capital Markets LLC is acting as the sole book-running manager for the offering.